Trial Profile
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients With Metastatic Breast Cancer With Expansion in Metastatic Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs PMD 026 (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Phoenix Molecular Designs
- 12 Dec 2023 Results (n=41) assessing impact of PMD-026 on hematological parameters presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Aug 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
- 15 Aug 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.